High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam

被引：44
作者：
Periasamy, Hariharan [1 ]
Joshi, Prashant [1 ]
Palwe, Snehal [1 ]
Shrivastava, Rahul [1 ]
Bhagwat, Sachin [1 ]
Patel, Mahesh [1 ]
机构：
[1] Wockhardt Res Ctr, Drug Discovery Res, Aurangabad, Maharashtra, India
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2020年 / 75卷 / 06期
关键词：
D O I：
10.1093/jac/dkaa021
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：1650 / 1651
页数：2
相关论文
共 11 条
  • [1] Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
    Alm, Richard A.
    Johnstone, Michele R.
    Lahiri, Sushmita D.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (05) : 1420 - 1428
  • [2] [Anonymous], 2019, BREAKP TABL INT MICS
  • [3] In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18
    Appalaraju, Boppe
    Baveja, Sujata
    Baliga, Shrikala
    Shenoy, Suchitra
    Bhardwaj, Renu
    Kongre, Vaishali
    Dattatraya, Gogi Suresh
    Dhole, Tapan
    Verma, Binita
    Mukherjee, D. N.
    Gupta, Shalini
    Shanmugam, Priyadarshini
    Iravane, Jyoti
    Mishra, Sudhi Ranjan
    Barman, Purabi
    Chopra, Shimpi
    Hariharan, Meenakshi
    Surpam, Rajendra
    Pratap, Rana
    Joshi, Prashant
    Khande, Hemant
    Mane, Ashish
    Jain, Rishi
    Bhagwat, Sachin
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) : 600 - 608
  • [4] Dean CR, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.01200-18, 10.1128/AAC.01200-18]
  • [5] Three Decades of β-Lactamase Inhibitors
    Drawz, Sarah M.
    Bonomo, Robert A.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) : 160 - +
  • [6] In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
    Kazmierczak, Krystyna M.
    Bradford, Patricia A.
    Stone, Gregory G.
    de Jonge, Boudewijn L. M.
    Sahm, Daniel F.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (12)
  • [7] Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates
    Sader, Helio S.
    Mendes, Rodrigo E.
    Pfaller, Michael A.
    Shortridge, Dee
    Flamm, Robert K.
    Castanheira, Mariana
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
  • [8] Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam
    Sieswerda, Elske
    van den Brand, Marre
    van den Berg, Roland B.
    Strater, Joris
    Schouls, Leo
    van Dijk, Karin
    Budding, Andries E.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) : 773 - 775
  • [9] Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing
    Tartof, SY
    Solberg, OD
    Manges, AR
    Riley, LW
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (12) : 5860 - 5864
  • [10] Penicillin-binding proteins and β-lactam resistance
    Zapun, Andre
    Contreras-Martel, Carlos
    Vernet, Thierry
    [J]. FEMS MICROBIOLOGY REVIEWS, 2008, 32 (02) : 361 - 385
12